BR0303475A - Sal cristalino do ácido adìpico da amlodipina, respectivo método de preparação e composição farmacêutica - Google Patents

Sal cristalino do ácido adìpico da amlodipina, respectivo método de preparação e composição farmacêutica

Info

Publication number
BR0303475A
BR0303475A BR0303475-5A BR0303475A BR0303475A BR 0303475 A BR0303475 A BR 0303475A BR 0303475 A BR0303475 A BR 0303475A BR 0303475 A BR0303475 A BR 0303475A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
crystalline salt
adipic acid
amlodipine
Prior art date
Application number
BR0303475-5A
Other languages
English (en)
Inventor
Dong Kwon Lim
Hyuk Koo Lee
Hea Ran Suh
Seong Hwan Cho
Kwang Hyeg Lee
Yun Cheul Kim
Sung Hak Jung
Sung Hak Lee
Hyn Suk Kang
Kyung Mi Park
Yun Taek Jung
Jun Hee Cheon
Choong Sil Park
Yong Sik Youn
Young Hoon Kim
Kyu Jeong Yeon
Myeong Yun Chae
Hae Tak Jin
Original Assignee
Cj Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020030053072A external-priority patent/KR100596369B1/ko
Application filed by Cj Corp filed Critical Cj Corp
Publication of BR0303475A publication Critical patent/BR0303475A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"SAL CRISTALINO DO áCIDO ADìPICO DA AMLODIPINA, RESPECTIVO MéTODO DE PREPARAçãO E COMPOSIçãO FARMACêUTICA". Proporcionam-se um novo sal cristalino de ácido orgânico de amlodipina com propriedades físico-químicas aperfeiçoadas, método de preparação do mesmo e composição farmacêutica que compreende o mesmo.
BR0303475-5A 2002-09-19 2003-09-08 Sal cristalino do ácido adìpico da amlodipina, respectivo método de preparação e composição farmacêutica BR0303475A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20020057328 2002-09-19
KR1020030053072A KR100596369B1 (ko) 2002-09-19 2003-07-31 결정형의 암로디핀 유기산염

Publications (1)

Publication Number Publication Date
BR0303475A true BR0303475A (pt) 2004-08-24

Family

ID=31949621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0303475-5A BR0303475A (pt) 2002-09-19 2003-09-08 Sal cristalino do ácido adìpico da amlodipina, respectivo método de preparação e composição farmacêutica

Country Status (6)

Country Link
US (1) US7015238B2 (pt)
EP (1) EP1400512A1 (pt)
JP (1) JP4365648B2 (pt)
AU (1) AU2003253460A1 (pt)
BR (1) BR0303475A (pt)
WO (1) WO2004026834A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100830003B1 (ko) * 2006-10-31 2008-05-15 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법
KR100843401B1 (ko) * 2006-12-04 2008-07-04 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
KR100840069B1 (ko) * 2007-01-23 2008-06-20 씨제이제일제당 (주) 결정성 ｓ-(-)-암로디핀 오로테이트 무수물 및 이의제조방법
TWI449704B (zh) * 2013-04-26 2014-08-21 Everlight Chem Ind Corp 嗎啡喃衍生物之結晶、其製造方法、及使用其之醫藥組成物
ES2886067T3 (es) 2016-10-07 2021-12-16 Silvergate Pharmaceuticals Inc Formulaciones de amlodipina
WO2018164937A1 (en) * 2017-03-06 2018-09-13 Dupont Nutrition Biosciences Aps Process for crystallizing 2'-fucosyllactose and related compositions
SG11201907911PA (en) * 2017-03-06 2019-09-27 Dupont Nutrition Biosci Aps Process for crystallizing 2'-fucosyllactose and related compositions
CN112334134A (zh) 2018-04-11 2021-02-05 希沃盖特制药公司 氨氯地平制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
PL189666B1 (pl) * 1998-04-09 2005-09-30 Adamed Sp Z Oo Sposób otrzymywania benzenosulfonianu amlodypiny
CN1163485C (zh) * 2000-09-15 2004-08-25 付俊昌 氨氯地平系列盐及其制备方法和用途
RS53403A (en) * 2000-12-29 2006-10-27 Pfizer Limited Process for making amlodipine maleate

Also Published As

Publication number Publication date
JP4365648B2 (ja) 2009-11-18
JP2004107342A (ja) 2004-04-08
EP1400512A1 (en) 2004-03-24
US20040058967A1 (en) 2004-03-25
WO2004026834A1 (en) 2004-04-01
AU2003253460A1 (en) 2004-04-08
US7015238B2 (en) 2006-03-21

Similar Documents

Publication Publication Date Title
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20035327D0 (no) Biologisk aktive metylen-blått derivater
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
WO2003009101A3 (en) Drug calendar apparatus and method
ATE350036T1 (de) Tetrahydroquinolin-derivate
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
NO941677D0 (no) Tetrazolderivater av gallesyrer, fremgangsmåter for fremstilling og deres anvendelse som legemiddel
NO20024772D0 (no) Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel
BR9906735A (pt) Composição farmacêutica lìquida aquosa
ECSP045221A (es) Sales de valsartan
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
BR0212069A (pt) Agentes antidiabéticos orais
BR0303475A (pt) Sal cristalino do ácido adìpico da amlodipina, respectivo método de preparação e composição farmacêutica
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7
DK0744397T3 (da) Fluorphenylsubstituerede alkenylcarboxylsyre-guanidiner som Na+/K+-antiport-inhibitorer, deres anvendelse som lægemiddel el
SI1970372T1 (sl) Soli 9-oksoakridin-10-ocetne kisline z 1-alkilamino-1-deoksi-polioli
MXPA03008250A (es) Nuevos derivados de diaminopirazol y colorantes que contienen estos compuestos.
BR0300698A (pt) Compostos derivados de quinazolina, um processo para sua preparação e composições farmacêuticas contendo-os
BRPI0418726A (pt) naftalenossulfonato de clopidogrel cristalino ou hidrato do mesmo, método para sua preparação e composição farmacêutica contendo o mesmo
BR0208504A (pt) Composição farmacêutica estável de pravastatina
EE200200599A (et) Tsüklipostiiniühend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,ühendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
BR0313076A (pt) Sal de ácido orgânico de amlodipina

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B25A Requested transfer of rights approved

Owner name: CJ CHEILJEDANG CORPORATION (KR)

Free format text: TRANSFERIDO DE: CJ CORP.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2387 DE 04-10-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.